TY - JOUR
T1 - Seeding drug discovery
T2 - integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells
AU - Keith, W. Nicol
AU - Thomson, Catherine M.
AU - Howcroft, Jill
AU - Maitland, Norman J.
AU - Shay, Jerry W.
N1 - Funding Information:
A British Association of Cancer Research (BACR) Special Conference entitled ‘Telomerase & Cancer Stem Cells: Exploiting Cellular Immortality for Therapeutic Gain’ was held in York, UK on 4–6 September 2006. During this meeting, three open surgery sessions were conducted to ascertain current opinion on the topics of Senescence, Cancer Stem Cells and Telomeres and Telomerase. The audience, which totalled 60, and mostly from Europe and the USA, comprised of key opinion leaders in each of the three related topic areas. The content of this report is based on this information and reported by the authors on behalf of the meeting. A number of participants are supported by Cancer Research UK and European Community grant LSHC-CT-2004-502943.
PY - 2007/8
Y1 - 2007/8
N2 - Telomerase activation is a hallmark of cancer. Advancement of telomerase as a therapeutic drug target has paved the way for translational opportunities in the related fields of senescence and cancer stem cells. Here, lessons may be learnt that can be applied to drug discovery, particularly with regard to the need to appreciate the relationships between telomerase, senescence and cancer stem cells. When considered as a time line to clinical trial, targeting of telomerase is leading the way to clinical proof-of-concept, with senescence and the cancer stem cell phenotype driving research concepts vital to maintaining a clinical development pipeline.
AB - Telomerase activation is a hallmark of cancer. Advancement of telomerase as a therapeutic drug target has paved the way for translational opportunities in the related fields of senescence and cancer stem cells. Here, lessons may be learnt that can be applied to drug discovery, particularly with regard to the need to appreciate the relationships between telomerase, senescence and cancer stem cells. When considered as a time line to clinical trial, targeting of telomerase is leading the way to clinical proof-of-concept, with senescence and the cancer stem cell phenotype driving research concepts vital to maintaining a clinical development pipeline.
UR - http://www.scopus.com/inward/record.url?scp=34547842088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547842088&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2007.06.009
DO - 10.1016/j.drudis.2007.06.009
M3 - Review article
C2 - 17706542
AN - SCOPUS:34547842088
SN - 1359-6446
VL - 12
SP - 611
EP - 621
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 15-16
ER -